SCHEMBL3918684

SCHEMBL3918684

CC(C)(C)c1ccc(OCC(=O)NCc2ccc3[nH]c(=O)[nH]c3c2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
MAPT P10636 5/20 0.52
HPGD P15428 5/20 0.52
ALDH1A1 P00352 4/20 0.52
KMT2A Q03164 4/20 0.52
NPSR1 Q6W5P4 3/20 0.52
MEN1 O00255 3/20 0.52
GAA P10253 2/20 0.52
G6PD P11413 1/20 0.52
BLM P54132 1/20 0.52
ADORA1 P30542 4/20 0.50
ADORA2B P29275 4/20 0.50
POLB P06746 3/20 0.45
HSD17B10 Q99714 3/20 0.45
ALOX15 P16050 2/20 0.45
USP2 O75604 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TAOK1 Q7L7X3 1/20 0.44
TAOK3 Q9H2K8 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3931516 0.88 KDM4E (0.52) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL3917823 0.85 MAOB (0.51) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL5992759 0.85 MAOB (0.46) HPGDADORA1ADORA2BALOX15TAOK1
SCHEMBL3932806 0.85 ADORA1 (0.47) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL3928617 0.84 ALDH1A1 (0.59) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL3917924 0.80 MAOB (0.48) HPGDKMT2AMEN1ADORA1ADORA2B
SCHEMBL3929061 0.79 ALDH1A1 (0.51) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL4640685 0.77 GRIN1 (0.48) ALDH1A1KMT2AMEN1ADORA1ADORA2B
SCHEMBL4640678 0.76 TRPV1 (0.52)
SCHEMBL4640484 0.75 GRIN1 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514457-B2 Substituted aryloxymethyl bicyclicmethyl acetamide compounds PFIZER INC. (US) 2009-04-07 US claimed
US-20060270682-A1 Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds PFIZER, INC. 2006-11-30 US claimed
US-7514457-B2 Substituted aryloxymethyl bicyclicmethyl acetamide compounds PFIZER INC. (US) 2009-04-07 US disclosed
US-7514457-B2 Substituted aryloxymethyl bicyclicmethyl acetamide compounds PFIZER INC. (US) 2009-04-07 US disclosed
US-7514457-B2 Substituted aryloxymethyl bicyclicmethyl acetamide compounds PFIZER INC. (US) 2009-04-07 US disclosed
US-20060270682-A1 Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds PFIZER, INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270682-A1 Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds NR0B1, NR0B2, NR2C2 KDM4E 3885/4885MAPT 4670/4885HPGD 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.